Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
125.23
-0.14 (-0.11%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Merck Announces Second-Quarter 2023 Financial Results
August 01, 2023
From
Merck & Co., Inc.
Via
Business Wire
7 Best Cancer Stocks to Invest in Now
July 28, 2023
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now.
Via
MarketBeat
Topics
Death
Exposures
Death
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer
July 28, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
July 27, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
July 26, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Fourth-Quarter 2023 Dividend
July 25, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive European Union CHMP Opinion for Gefapixant
July 21, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
July 21, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
July 19, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1
June 29, 2023
From
Merck & Co., Inc.
Via
Business Wire
PetVivo Sales Spryng Higher on Injectable OA Relief for Pets
June 27, 2023
Developmental biomedical device company PetVivo Holdings Inc. (NASDAQ: PETV) makes pet medical devices and therapeutics. What kind of medical devices would
Via
MarketBeat
Red Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover
June 21, 2023
The market’s initial positive reaction to the DICE Therapeutics news suggests Eli Lilly shares will continue to sizzle this summer.
Via
MarketBeat
Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
June 20, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Completes Acquisition of Prometheus Biosciences, Inc.
June 16, 2023
From
Merck & Co., Inc.
Via
Business Wire
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
June 16, 2023
From
Merck & Co., Inc.
Via
Business Wire
U.S. District Court for the District of New Jersey Rules in Favor of Merck in Patent Infringement Lawsuit Related to BRIDION® (sugammadex)
June 13, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at EASL 2023
June 12, 2023
From
Merck & Co., Inc.
Via
Business Wire
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer
June 08, 2023
From
Merck & Co., Inc.
Via
Business Wire
U.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients
June 06, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Merck & Co., Inc.
Via
Business Wire
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma
June 05, 2023
Via
ACCESSWIRE
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC
June 03, 2023
From
Merck & Co., Inc.
Via
Business Wire
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
June 03, 2023
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
June 01, 2023
From
Merck & Co., Inc.
Via
Business Wire
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
May 30, 2023
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Admin
Via
MarketBeat
Topics
Death
Exposures
Death
Product Safety
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
May 25, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Third-Quarter 2023 Dividend
May 23, 2023
From
Merck & Co., Inc.
Via
Business Wire
Doximity is an Overlooked Medical Ecosystem AI Play
May 23, 2023
Doximity Inc. (NASDAQ: DOCS) is a digital professional social network platform for medical practitioners. It’s a medical community networking platform like
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
May 18, 2023
Big pharma stocks Novartis, Eli Lilly, Merck, and Novo Nordisk are outperforming the market, driven by successful drugs and strong earnings growth.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting
May 15, 2023
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.